住友ファーマ company information, Employees & Contact Information

Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis PR Newswire

Establishment of a Pharmaceutical Strategic Platform： Succession of Sumitomo Pharma’s Business in Asia marubeni.com

Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio Yahoo Finance

Japan's Marubeni takes on Sumitomo's Asia pharma business to make new company in deal worth up to $480M Fierce Pharma

Sumitomo Pharma : Presents Latest Clinical Data on Investigational Anti-Cancer Agent Enzomenib (DSP-5336) at the 2025 Annual Meeting of the Japanese Society of Hematology (JSH) MarketScreener

Sumitomo Pharma America and Former Professional Quarterback Rodney Peete Say it's Time to Go™ and Put Yourself First with Overactive Bladder Treatment Option GEMTESA® PR Newswire

Power couple Peetes team up to promote Sumitomo’s Gemtesa Fierce Pharma

Sumitomo Pharma America enters into a Cooperative Research and Development Agreement with the National Cancer Institute to Advance Clinical Understanding of Enzomenib PR Newswire

Sumitomo brings together Gemtesa 'Go-Getters' to discuss overactive bladder symptoms Fierce Pharma

Sumitomo Pharma America Presents New Data on Vibegron at the 2025 American Urological Association Annual Meeting PR Newswire

UPDATED: Most expensive drugs in the US in 2025 Fierce Pharma

Sumitomo Pharma America and Actor Holly Robinson Peete Encourage People with Overactive Bladder to Speak Up and Seek Treatment PR Newswire

Fierce Pharma Asia—Pharma CEOs meet Xi Jinping; Trump's tariffs; BioNTech's bispecific data Fierce Pharma

Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA® (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia PR Newswire

Sumitomo Pharma, suffering from sliding sales, lays off another 400 US staffers Fierce Pharma

Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting PR Newswire

Fierce Pharma Asia—Sanofi's $1B manufacturing base; GSK's ADC deal, Shingrix recalibration in China Fierce Pharma

Sumitomo Pharma's new CEO weighs layoffs in Japan after sharp sales drop, US job cuts: report Fierce Pharma

Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities PR Newswire

Sumitomo Pharma America to Present Preliminary Clinical Data Evaluating Investigational Oncology Agents TP-3654 and DSP-5336 at the American Society of Hematology Annual Meeting PR Newswire

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist PR Newswire

Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences PR Newswire

Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia PR Newswire

Fierce Pharma Asia—BMS, BeiGene strike settlement; Sumitomo, Otsuka suffer trial failures; AZ's CEO talks China Fierce Pharma

Fierce Pharma Asia—Eisai's Leqembi outlook; Sumitomo's downsizing; Kyowa Kirin's expansion Fierce Pharma

Sumitomo Pharma tidies up 7 units into one combined US entity in spring cleaning Fierce Biotech

Sumitomo's improved buyout offer sways Myovant FirstWord Pharma

Sumitomo Dainippon Pharma Adopts Veeva Vault RIM Applications Veeva

Evaluation of OCT2-mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia British Pharmacological Society | Journals

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement PR Newswire

Sumitomo Pharma America and Actress Holly Robinson Peete Extend Time To Go™ Campaign to Empower People with Overactive Bladder PR Newswire

Poxel to receive sales-based payment and higher level of royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® Achieving JPY 5 billion Net Sales in Japan Yahoo Finance

Otsuka, Sumitomo blame high placebo response for ulotaront pivotal study failures FirstWord Pharma

Jazz Acquires Narcolepsy Hopeful DSP-0187 in Agreement With Sumitomo Pharma NeurologyLive

Jazz teams up with Sumitomo on sleep disorder drug DSP-0187 FirstWord Pharma

Biopharma layoffs roll on as Novartis, Sumitomo and Valneva plot around 800 cuts Fierce Pharma

Sumitomo anoints actor as first ‘Gemtesa Go-Getter’ in extended overactive bladder campaign Fierce Pharma

EU okays Pierre Fabre’s Obgemsa to treat overactive bladder symptoms FirstWord Pharma

Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration Business Wire

Otsuka, Sunovion ink deal to develop four drugs for neuropsychiatric conditions FirstWord Pharma

Fierce Pharma Asia—Daiichi, Merck's FDA rejection; Wegovy's expansion; Takeda CEO's hunt for China deals Fierce Pharma

Japan's Marubeni to buy Sumitomo Pharma's Asia business for $300m Nikkei Asia

FDA approves vibegron for OAB symptoms in pharmacologically treated BPH Urology Times

Relugolix now available in Canada for advanced prostate cancer Urology Times

Poxel Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG® Package Insert to Include Type 2 Diabetes Patients with Renal Impairment Yahoo Finance

BBOT Appoints Uneek Mehra as Chief Financial Officer Contract Pharma

FDA Grants Orphan Drug Designation to TP-1287 for Ewing Sarcoma OncLive

Inovio names chief commercial officer, putting Merck vet in charge of launch preparations Fierce Pharma

Data breach at pharma partner Cencora puts sensitive patient information at risk Fierce Pharma

TherapeuticsMD lays off entire workforce after licensing products out for $153M Fierce Pharma

After U.S. job cuts, Sumitomo Pharma eyes layoffs in Japan Nikkei Asia

Bristol Myers telegraphs layoffs in New Jersey, trimming 117 jobs in staggered wave of cuts Fierce Pharma

Dainippon Sumitomo Pharma Co., Ltd.'s Sunovion Pharmaceuticals Inc. (SEPR)'s Schizophrenia Pill, Latuda Gets FDA Nod Fierce Biotech

Sunovion cashes in sublingual Parkinson's drug, selling EU rights to Bial Fierce Pharma

Neurocrine gives up on Parkinson's drug Ongentys, citing 'unsustainable' launch Fierce Pharma

Sumitomo Pharma seeks approval for world's first iPS cell therapy for Parkinson's disease - CHOSUNBIZ Chosun Biz

Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update FinancialContent

Sunovion Pharmaceuticals Inc. to Divest Xopenex® (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc. Fierce Pharma

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda® (Lurasidone Hydrochloride) in Europe PR Newswire UK

FDA Approves Once-Daily LATUDA® (lurasidone HCL) for the Treatment of Patients with Schizophrenia Fierce Biotech